-
Je něco špatně v tomto záznamu ?
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)
P. Turton, D. El-Sharkawi, I. Lyburn, B. Sharma, P. Mahalingam, SD. Turner, F. MacNeill, L. Johnson, S. Hamilton, C. Burton, N. Mercer
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, přehledy
- MeSH
- anaplastický velkobuněčný lymfom diagnóza etiologie patologie terapie MeSH
- lidé MeSH
- nádory prsu diagnóza etiologie patologie terapie MeSH
- protinádorové látky terapeutické užití MeSH
- prsní implantáty škodlivé účinky MeSH
- radioterapie MeSH
- staging nádorů MeSH
- určení symptomu MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK) negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimize the need for systemic treatments, reduce morbidity and the risk of poor outcomes. These guidelines provide an evidence-based and systematic framework for the assessment and treatment of patients with suspected or proven BIA-ALCL and are aimed at all clinicians involved in the care of people with breast implants.
Barts Health NHS Trust London UK
Bristol Plastic Surgery 58 Queen Square Bristol BS1 4LF
CEITEC Masaryk University Brno Czech Republic
Cobalt Medical Charity Cheltenham UK
Gloucestershire Hospitals NHS Foundation Trust UK
Royal Marsden NHS Foundation Trust London UK
St James's Hospital The Leeds Teaching Hospitals NHS Trust Leeds UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011665
- 003
- CZ-PrNML
- 005
- 20210507103313.0
- 007
- ta
- 008
- 210420s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bjps.2020.10.064 $2 doi
- 035 __
- $a (PubMed)33483089
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Turton, Philip $u St James's Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: philip.turton@nhs.net
- 245 10
- $a UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG) / $c P. Turton, D. El-Sharkawi, I. Lyburn, B. Sharma, P. Mahalingam, SD. Turner, F. MacNeill, L. Johnson, S. Hamilton, C. Burton, N. Mercer
- 520 9_
- $a Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK) negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimize the need for systemic treatments, reduce morbidity and the risk of poor outcomes. These guidelines provide an evidence-based and systematic framework for the assessment and treatment of patients with suspected or proven BIA-ALCL and are aimed at all clinicians involved in the care of people with breast implants.
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a prsní implantáty $x škodlivé účinky $7 D018427
- 650 _2
- $a nádory prsu $x diagnóza $x etiologie $x patologie $x terapie $7 D001943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a anaplastický velkobuněčný lymfom $x diagnóza $x etiologie $x patologie $x terapie $7 D017728
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a radioterapie $7 D011878
- 650 _2
- $a určení symptomu $7 D063189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a El-Sharkawi, Dima $u Royal Marsden NHS Foundation Trust, London, UK
- 700 1_
- $a Lyburn, Iain $u Cobalt Medical Charity, Cheltenham, UK; Gloucestershire Hospitals NHS Foundation Trust, UK
- 700 1_
- $a Sharma, Bhupinder $u Royal Marsden NHS Foundation Trust, London, UK
- 700 1_
- $a Mahalingam, Preethika $u Royal Marsden NHS Foundation Trust, London, UK
- 700 1_
- $a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK; CEITEC, Masaryk University, Brno, Czech Republic
- 700 1_
- $a MacNeill, Fiona $u Royal Marsden NHS Foundation Trust, London, UK
- 700 1_
- $a Johnson, Laura $u Barts Health NHS Trust, London, UK
- 700 1_
- $a Hamilton, Stephen $u Royal Free Hospital, London, UK
- 700 1_
- $a Burton, Cathy $u St James's Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 700 1_
- $a Mercer, Nigel $u Bristol Plastic Surgery, 58 Queen Square, Bristol BS1 4LF
- 773 0_
- $w MED00008968 $t Journal of plastic, reconstructive & aesthetic surgery : JPRAS $x 1878-0539 $g Roč. 74, č. 1 (2021), s. 13-29
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33483089 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507103312 $b ABA008
- 999 __
- $a ok $b bmc $g 1650129 $s 1132044
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 74 $c 1 $d 13-29 $e 20201112 $i 1878-0539 $m Journal of plastic, reconstructive & aesthetic surgery $n J Plast Reconstr Aesthet Surg $x MED00008968
- LZP __
- $a Pubmed-20210420
